DEA Faces Lawsuit Seeking To Reveal Emails Between Agency And Anti-Marijuana Group About Rescheduling Process
Trump’s Choice For Surgeon General Voiced Support For Medical Marijuana, But Also Linked Cannabis Use To Heart Problems
Maryland Government’s Psychedelics Task Force Begins Work On Recommendations Due To Lawmakers Next Year
Federal Agency Wants People Who Have ‘Lived Or Living Experience With Drug Use’ To Help Shape Research Agenda
Australia’s Senate Votes Down Marijuana Legalization Bill
Legalizing Medical Marijuana In Utah Helped Reduce Opioid Use By Pain Patients, Study Finds
Adding Marijuana To State Prescription Drug Monitoring Programs Reduces Prescribing Of Scheduled Narcotics, Study Shows
Lesser-Known Marijuana Component CBG Is A ‘Promising Therapeutic Agent’ With Potential To Treat Cancer And Pain, Study Says
Marijuana Has ‘No Significant Harmful Effects’ On Age-Related Cognitive Decline, Study Shows
FDA Approves Long-Awaited Clinical Trial Of Smoked Marijuana To Treat PTSD In Veterans
Marijuana Vape Company Slams Instagram And Meta For Blocking Cannabis-Related Social Media Content
Most Marijuana Consumers Are Spending More Money On Cannabis Now Than They Were Last Year, Poll Finds
Health And Wellness Benefits Of Marijuana Are A Primary Draw For Women, Poll Finds, While Price Is A Key Concern
Nevada Officials Adopt Rule To Stop Penalizing Boxers And MMA Fighters Over Marijuana
Snoop Dogg Confirms He Has A Staffer Who Makes Sure People He’s Smoking Marijuana With Don’t Get Too High
Michigan’s Legal Marijuana Market Is Poised To Surpass $10 Billion In Total Recreational Sales By Year’s End
Florida Officials Announce 22 New Medical Marijuana Business License Winners, Weeks After Recreational Legalization Failed
New York’s Legal Marijuana Market Set To Pass $1 Billion In Sales By End Of 2024
Arizona Marijuana Sales Hit Lowest Monthly Total Of 2024 In September As Recreational Purchases Continue To Slide
Missouri’s Marijuana Market Is Outperforming States With Older Legalization Laws
Legalizing Medical Marijuana In Utah Helped Reduce Opioid Use By Pain Patients, Study Finds
Australia’s Senate Votes Down Marijuana Legalization Bill
Kentucky Holds Lottery To Award First Medical Marijuana Dispensary Licenses
Anti-Marijuana GOP Congressman Presses Top Federal Health Official On Rescheduling Process
Georgia Senate Committee Recommends $5 Million Investment To Research Psychedelic-Assisted Therapy For PTSD
Michigan nears $10 billion in marijuana sales (Newsletter: November 29, 2024)
DEA judge won’t remove agency from cannabis hearing (Newsletter: November 28, 2024)
DEA says health officials “rejected” cannabis rescheduling hearing invite (Newsletter: November 27, 2024)
DEA denies illegal cannabis communications with prohibitionists (Newsletter: November 26, 2024)
Trump’s new AG opposed medical cannabis legalization (Newsletter: November 25, 2024)
Published
on
By
A newly published review of research on marijuana and chronic nerve pain concludes that treatment with cannabinoids offers “significant relief from chronic pain” with “minimal to no side effects”—potentially providing patients a “life-changing alternative” to conventional pharmaceuticals.
“The positive effects of cannabinoids in pain management are clear and their merit in the treatment thereof is evident,” says the research, published last month in the journal Cureus. It adds that “the fact that cannabinoids are natural garners it support over traditional synthetic and semi-synthetic drugs.”
Authors considered thousands of research papers for the review, ultimately including in their analysis five placebo-controlled randomized control studies published between 2000 and 2024. They found that treatment with cannabinoids offered markedly more pain relief than did placebo.
“Compared to placebo, cannabinoids provided significant relief from chronic pain (33% vs 15%) as measured by the visual analog scale,” the paper says. “The transdermal application of CBD led to a more pronounced reduction in sharp pain, according to the neuropathic pain scale. Minimal to no side effects were recorded, further highlighting the potential benefits of cannabinoids.”
Authors, from Sir Seewoosagur Ramgoolam Medical College, in Mauritius, noted that while there’s still “insufficient evidence available on their long-term adverse effects and drug interactions, due to their ambiguous legal status and heightened social taboos globally,” the results indicate that cannabinoids nevertheless offer a paradigm-changing alternative to pharmaceuticals.
“The potential benefit of cannabinoids is that they are naturally derived drugs that have already been shown to have the potential to effectively decrease chronic pain with minimal side effects as compared to the standard drugs being used,” the review concludes. “The ability of cannabinoids to provide pain relief with minimal side effects and concurrently be a naturally derived product may potentially be a life-changing alternative that the pharmaceutical market is in dire need of.”
The research looked specifically at neuropathic pain, caused by damage to or dysfunction of the nervous system and often associated with conditions such as diabetes, HIV/AIDS, shingles, multiple sclerosis and even side-effects from certain pharmaceutical drugs or radiation therapy. Treatment of such pain “is a complex endeavor,” the paper notes, “which often requires specialist care and intensive drug therapy.”
“Cannabis-derived drugs in their most effective formulation and dosage can be a major breakthrough in the treatment of chronic pain,” authors continue. “It is thus obvious that a greater emphasis should be put on medical cannabis as a treatment option through larger scale clinical trials.”
As more states have legalized medical marijuana, pain has been a top qualifying condition in most jurisdictions. That’s backed up by reports from patients and health care providers indicating that cannabis is an effective tool for pain management.
A research letter published last month by the American Medical Association, for example, found that 71 percent of chronic pain patients and 59 percent of physicians are in favor of nationally legalizing medical cannabis. The study involved interviews with 1,661 chronic pain patients and 1,000 doctors. It was partly funded by the National Institute on Drug Abuse (NIDA).
“Overall, people with chronic pain were more supportive of the policies that would expand access to medical cannabis, and providers were more supportive of the policies that would restrict access to medical cannabis,” said Elizabeth Stone, the lead author of the study at the Rutgers Institute for Health, Health Care Policy and Aging Research.
Meanwhile, the National Cancer Institute (NCI) also recently published a wide-ranging series of scientific reports on marijuana and cancer as part of an effort to better understand “core questions” around patients’ relationship with cannabis—including sourcing, cost, behavioral patterns, patient–provider communications and reasons for use.
One of the studies looked specifically at patients who use medical marijuana as an alternative to opioids to treat their cancer-related pain.
Another study published last month found that patients who used medical marijuana for three months improved on a variety of health-related quality of life (HRQoL) measures, including physical functioning, bodily pain, social functioning, fatigue and general health.
Patients who used a CBD vaginal suppository in a separate trial, meanwhile, also reported significantly reduced menstrual pain and related symptoms. Participants who used the CBD suppository generally reported less period pain, better mood and lower use of pain medications compared to subjects who underwent conventional treatment.
A study published this summer, meanwhile, found that more than half (57 percent) of patients with chronic musculoskeletal pain said cannabis was more effective than other analgesic medications, while 40 percent reported reducing their use of other painkillers since they began using marijuana.
Among those who said they used cannabis to manage pain, the most commonly used cannabinoid was CBD (39 percent), followed by a hybrid of multiple cannabinoids (20 percent). But almost a quarter (23 percent) said they were unaware of their cannabis’s composition.
Yet another study last year, published by the American Medical Association, found that the use of medical marijuana was associated with “significant improvements” in quality of life for people with chronic conditions like pain and insomnia—and those effects were “largely sustained” over time.
There’s ‘No Linear Relationship Of Blood THC To Driving,’ Study Finds, Calling Into Question Many State Marijuana-Impaired Driving Laws
Photo courtesy of Philip Steffan.
Medical Marijuana Improves Chronic Pain And Mental Health Symptoms While Reducing Prescription Drug Use, Study Shows
There’s ‘No Linear Relationship Of Blood THC To Driving,’ Study Finds, Calling Into Question Many State Marijuana-Impaired Driving Laws
Ben Adlin, a senior editor at Marijuana Moment, has been covering cannabis and other drug policy issues professionally since 2011. He was previously a senior news editor at Leafly, an associate editor at the Los Angeles Daily Journal and a Coro Fellow in Public Affairs. He lives in Washington State.
DEA Faces Lawsuit Seeking To Reveal Emails Between Agency And Anti-Marijuana Group About Rescheduling Process
Trump’s Choice For Surgeon General Voiced Support For Medical Marijuana, But Also Linked Cannabis Use To Heart Problems
Legalizing Medical Marijuana In Utah Helped Reduce Opioid Use By Pain Patients, Study Finds
Michigan nears $10 billion in marijuana sales (Newsletter: November 29, 2024)
Maryland Government’s Psychedelics Task Force Begins Work On Recommendations Due To Lawmakers Next Year
Adding Marijuana To State Prescription Drug Monitoring Programs Reduces Prescribing Of Scheduled Narcotics, Study Shows
All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell
Cannabis Treatment Reduces Chronic Nerve Pain With 'Minimal To No Side Effects,' New Scientific Review Finds – Marijuana Moment
